Skip to main content

Chembio, LumiraDx Partner to Develop Coronavirus Tests

NEW YORK – Chembio Diagnostics said on Thursday it has entered a worldwide strategic partnership with LumiraDx to develop point-of-care diagnostic tests for the detection of SARS-CoV-2 and IgM and IgG antibodies to the coronavirus on both firm's diagnostic platforms.

The strategic partnership expands on an existing collaboration between the companies. In 2018, they announced an agreement to develop point-of-care diagnostic tests for infectious diseases to address significant global health threats.

The strategic partnership associated with developing coronavirus point-of-care tests "demonstrates our scientific expertise and the versatility of our DPP platform," Gail Page, interim CEO of Hauppauge, New York-based Chembio, said in a statement.

Financial and other terms of the strategic agreement were not disclosed.